Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice

Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice

Scavenger receptor class B member 3, also known as cluster of differentiation-36 (CD36) receptor, is involved in the uptake and accumulation of modified lipoprotein in macrophages, driving atherosclerosis progression. Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been develo...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis Vol. 307; pp. 52 - 62
Main Authors: Frégeau, Geneviève, Sarduy, Roger, Elimam, Hanan, Esposito, Cloé L., Mellal, Katia, Ménard, Liliane, Leitão da Graça, Silas D., Proulx, Caroline, Zhang, Jinqiang, Febbraio, Maria, Soto, Yosdel, Lubell, William D., Ong, Huy, Marleau, Sylvie
Format: Journal Article
Language:English
Published: Elsevier B.V 01-08-2020
Subjects:
Atherosclerosis
Azapeptides
CD36
Macrophages
Regression
Regression
Azapeptides
CD36
Macrophages
Atherosclerosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Scavenger receptor class B member 3, also known as cluster of differentiation-36 (CD36) receptor, is involved in the uptake and accumulation of modified lipoprotein in macrophages, driving atherosclerosis progression. Azapeptide analogs of growth hormone-releasing peptide-6 (GHRP-6) have been developed as selective CD36 ligands and evaluated for their anti-atherosclerotic properties in apoe−/− mice. From 4 to 19 weeks of age, male apoe−/− mice were fed a high fat high cholesterol (HFHC) diet, then switched to normal chow and treated daily with 300 nmol/kg of MPE-001 ([aza-Tyr4]-GHRP-6) or MPE-003 ([aza-(N,N-diallylaminobut-2-ynyl)Gly4]-GHRP-6) for 9 weeks. In another protocol, mice were fed a HFHC diet throughout the study. Azapeptides decreased lesion progression in the aortic arch and reduced aortic sinus lesion areas below pre-existing lesions levels in apoe−/− mice which were switched to chow diet. In mice fed a HFHC throughout the study, azapeptides reduced lesion progression in the aortic vessel and sinus. The anti-atherosclerotic effect of azapeptides was associated with a reduced ratio of iNOS+/CD206+ macrophages within lesions, and lowered plasma inflammatory cytokine levels. Monocytes from azapeptide-treated mice showed altered mitochondrial oxygen consumption rates, consistent with an M2-like phenotype. These effects were dependent on CD36, and not observed in apoe−/−cd36−/− mice. Azapeptides MPE-001 and MPE-003 diminished aortic lesion progression and reduced, below pre-existing levels, lesions in the aortic sinus of atherosclerotic mice. A relative increase of M2-like macrophages was observed in lesions, associated with reduced systemic inflammation. Development of CD36-selective azapeptide ligands merits consideration for treating atherosclerotic disease. [Display omitted] •Azapeptide analogs of GHRP-6 were synthesized as selective CD36 ligands.•Azapeptides elicit lesion regression in aortic sinus in a CD36-dependent manner.•Azapeptides halted atherosclerotic lesion development in aorta.•Azapeptides induce macrophage skewing towards the anti-inflammatory phenotype.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2020.06.010